Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Vitamin B12 is a multi-ingredient topical solution used primarily for the treatment and prevention of oral mucositis, particularly in patients undergoing chemoradiotherapy for head and neck cancers such as nasopharyngeal carcinoma. The formulation typically consists of cyanocobalamin (Vitamin B12), dexamethasone, and lidocaine. Cyanocobalamin is included to facilitate mucosal tissue repair and epithelial regeneration. Dexamethasone, a potent corticosteroid, serves to reduce local inflammation and edema, while lidocaine provides symptomatic relief through local anesthesia. This combination is often used as a mouthwash or local application to reduce the severity and duration of radiation-induced oral lesions and is frequently evaluated in combination with growth factors like rhGM-CSF.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound vitamin b12.